Showing results (61-70 of 90) with videos related to
Sort By:
Pageof 9
Journal of Clinical Pharmacology|April 5, 2013
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysisBrian I Rini, May Garrett, Bill Poland, et al.Cancer|September 16, 2008
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group studyMichael B Atkins, Jeffrey A Sosman, Sanjiv Agarwala, et al.Journal of Cancer Research and Clinical Oncology|May 18, 2007
Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer ConsortiumKim Margolin, Timothy W Synold, Primo Lara, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinomaRobert J Motzer, Gary R Hudes, Brendan D Curti, et al.Cancer|July 2, 2003
Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology GroupArthur I Radin, Haesook T Kim, Barbara W Grant, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancerKim Margolin, Michael B Atkins, Janice P Dutcher, et al.The Oncologist|September 10, 2008
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinibMario E Lacouture, Shenhong Wu, Caroline Robert, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinomaMichael B Atkins, Manuel Hidalgo, Walter M Stadler, et al.Leukemia & Lymphoma|December 29, 2004
Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group (E1993)Janice P Dutcher, Sandra Lee, Robert E Gallagher, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 1, 2007
Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group studyJoseph I Clark, Jessica Mehrabi, Jeffrey A Sosman, et al.Pageof 9